 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LY3849891 / Eli Lilly
Trial completion date, Trial primary completion date: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Jun 25, 2024
P1, N=176, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Dec 2025
- ||| LY3849891 / Eli Lilly
Enrollment open: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Oct 23, 2023
P1, N=176, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Dec 2025 Active, not recruiting --> Recruiting
- || LY3849891 / Eli Lilly
Enrollment closed: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Oct 11, 2023
P1, N=176, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| LY3849891 / Eli Lilly
Enrollment open: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Jun 23, 2022
P1, N=176, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| LY3849891 / Eli Lilly
New P1 trial: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - May 26, 2022
P1, N=176, Not yet recruiting, Sponsor: Eli Lilly and Company